[go: up one dir, main page]

AR102527A1 - Vacunas terapéuticas para hpv16 - Google Patents

Vacunas terapéuticas para hpv16

Info

Publication number
AR102527A1
AR102527A1 ARP150103569A ARP150103569A AR102527A1 AR 102527 A1 AR102527 A1 AR 102527A1 AR P150103569 A ARP150103569 A AR P150103569A AR P150103569 A ARP150103569 A AR P150103569A AR 102527 A1 AR102527 A1 AR 102527A1
Authority
AR
Argentina
Prior art keywords
hpv16
therapeutic vaccines
nucleic acid
polypeptide
encodes
Prior art date
Application number
ARP150103569A
Other languages
English (en)
Inventor
Khan Selina
Gilles Uil Taco
Oosterhuis Koen
Christiaan Scheper Gerrit
Hubertina Henricus Custers Jerme
Margaretha Bunnik Evelien
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52020908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR102527(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR102527A1 publication Critical patent/AR102527A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)

Abstract

Construcciones de ácidos nucleicos y polipéptidos de diseño que se pueden utilizar como vacunas terapéuticas contra el HPV16. Reivindicación 1: Una molécula de ácido nucleico caracterizada porque codifica un polipéptido que comprende la SEQ ID Nº 1.
ARP150103569A 2014-11-04 2015-11-04 Vacunas terapéuticas para hpv16 AR102527A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04

Publications (1)

Publication Number Publication Date
AR102527A1 true AR102527A1 (es) 2017-03-08

Family

ID=52020908

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103569A AR102527A1 (es) 2014-11-04 2015-11-04 Vacunas terapéuticas para hpv16

Country Status (34)

Country Link
US (4) US9701721B2 (es)
EP (2) EP3215187B1 (es)
JP (2) JP6325751B2 (es)
KR (1) KR20170083562A (es)
CN (1) CN107075521B (es)
AR (1) AR102527A1 (es)
AU (2) AU2015341926B2 (es)
BR (1) BR112017009177A2 (es)
CA (1) CA2965562C (es)
CL (1) CL2017001089A1 (es)
CO (1) CO2017004838A2 (es)
CY (1) CY1121377T1 (es)
DK (1) DK3215187T3 (es)
EA (1) EA035461B1 (es)
ES (1) ES2697903T3 (es)
HR (1) HRP20181895T1 (es)
HU (1) HUE040440T2 (es)
IL (1) IL251895B (es)
LT (1) LT3215187T (es)
MA (2) MA46378A (es)
MD (1) MD3215187T2 (es)
MX (1) MX379069B (es)
MY (1) MY181175A (es)
NZ (1) NZ730802A (es)
PL (1) PL3215187T3 (es)
PT (1) PT3215187T (es)
RS (1) RS58080B1 (es)
SA (1) SA517381457B1 (es)
SG (1) SG11201702997YA (es)
SI (1) SI3215187T1 (es)
SM (1) SMT201800602T1 (es)
TW (2) TWI694147B (es)
WO (1) WO2016071306A1 (es)
ZA (1) ZA201703055B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
EP3337500A1 (en) 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
SG11201808809PA (en) * 2016-05-02 2018-11-29 Janssen Vaccine & Prevention B V Therapeutic hpv vaccine combinations
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
WO2018187356A2 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
MY201967A (en) * 2017-09-23 2024-03-27 Boehringer Ingelheim Pharma Paramyxoviridae expression system
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
TW202003025A (zh) * 2018-03-12 2020-01-16 美商Ｓｑｚ生物科技公司 用於治療ｈｐｖ相關疾病之方法
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
CN114555129A (zh) 2019-09-20 2022-05-27 特兰斯吉恩股份有限公司 编码hpv多肽和il-2的痘病毒与抗pd-l1抗体的组合
US20230277645A1 (en) * 2020-04-02 2023-09-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2021228816A1 (en) * 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
CA3200064A1 (en) * 2020-11-24 2022-06-02 Ma, Muchou Joe Dna vaccine for human palillomavirus and method for using the same
JP2024539188A (ja) * 2021-10-22 2024-10-28 イノビオ ファーマシューティカルズ，インコーポレイティド 肛門高悪性度扁平上皮内病変（ｈｓｉｌ）を治療するための組成物及び方法
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗
CN120607593A (zh) * 2024-03-06 2025-09-09 诺未生物技术(无锡)有限公司 治疗hpv感染相关疾病的药物
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1550722B1 (en) 1999-05-17 2007-06-13 Crucell Holland B.V. Recombinant human adenovirus serotype 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU1152402A (en) 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
PT1335987E (pt) 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
WO2005080556A2 (en) 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
CA2581422C (en) 2004-11-08 2012-05-22 Chromagenics B.V. Selection of host cells expressing protein at high levels
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
CA2638757C (en) 2006-02-28 2014-01-21 Vaxart, Inc. Chimeric adenoviral vectors
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
BRPI0806350A2 (pt) * 2007-01-30 2011-09-06 Transgene Sa uso de uma molécula de ácido nucléico, uso de um vetor, uso de um particula viral infecciosa, vetores, particula viral infecciosa e composição
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
NZ593235A (en) 2008-11-03 2013-02-22 Crucell Holland Bv Method for the production of recombinant adenovirus serotype 35
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
ES2666720T3 (es) * 2010-08-13 2018-05-07 Genexine, Inc Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US10576141B2 (en) 2014-09-03 2020-03-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
EP3337500A1 (en) * 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
SG11201808809PA (en) * 2016-05-02 2018-11-29 Janssen Vaccine & Prevention B V Therapeutic hpv vaccine combinations

Also Published As

Publication number Publication date
PL3215187T3 (pl) 2019-04-30
JP2017534286A (ja) 2017-11-24
EA035461B1 (ru) 2020-06-19
SI3215187T1 (sl) 2019-02-28
CN107075521B (zh) 2021-06-08
MD3215187T2 (ro) 2019-02-28
EA201790976A1 (ru) 2017-09-29
JP6325751B2 (ja) 2018-05-16
TW201617450A (zh) 2016-05-16
CN107075521A (zh) 2017-08-18
JP2018148890A (ja) 2018-09-27
EP3215187B1 (en) 2018-08-29
EP3421046A1 (en) 2019-01-02
US20160122396A1 (en) 2016-05-05
US10555996B2 (en) 2020-02-11
CA2965562C (en) 2023-11-21
MA40902B1 (fr) 2018-12-31
BR112017009177A2 (pt) 2018-12-11
CA2965562A1 (en) 2016-05-12
US20180344841A1 (en) 2018-12-06
US20200164057A1 (en) 2020-05-28
AU2018282463B2 (en) 2020-09-10
SMT201800602T1 (it) 2019-01-11
TW202043476A (zh) 2020-12-01
IL251895A0 (en) 2017-06-29
IL251895B (en) 2019-08-29
MX379069B (es) 2025-03-10
PT3215187T (pt) 2018-11-27
HUE040440T2 (hu) 2019-03-28
WO2016071306A1 (en) 2016-05-12
DK3215187T3 (en) 2018-12-10
MX2017005788A (es) 2017-08-02
AU2015341926A1 (en) 2017-04-27
ZA201703055B (en) 2019-11-27
US9701721B2 (en) 2017-07-11
KR20170083562A (ko) 2017-07-18
MA40902A (fr) 2017-09-13
AU2015341926B2 (en) 2018-09-27
TWI694147B (zh) 2020-05-21
CY1121377T1 (el) 2020-05-29
US20170281747A1 (en) 2017-10-05
MA46378A (fr) 2019-08-07
CL2017001089A1 (es) 2017-12-29
TWI731654B (zh) 2021-06-21
HRP20181895T1 (hr) 2019-01-11
US11040096B2 (en) 2021-06-22
MY181175A (en) 2020-12-21
JP6606571B2 (ja) 2019-11-13
NZ730802A (en) 2021-12-24
EP3215187A1 (en) 2017-09-13
AU2018282463A1 (en) 2019-01-24
SA517381457B1 (ar) 2021-03-11
CO2017004838A2 (es) 2017-07-28
RS58080B1 (sr) 2019-02-28
SG11201702997YA (en) 2017-05-30
US10071151B2 (en) 2018-09-11
LT3215187T (lt) 2018-12-27
ES2697903T3 (es) 2019-01-29

Similar Documents

Publication Publication Date Title
AR102527A1 (es) Vacunas terapéuticas para hpv16
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
AR095233A1 (es) Métodos y composiciones para el control de malezas
MX2021004479A (es) Agentes biologicos y su uso en plantas.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2017001369A1 (es) Proceso para manipular el nivel del contenido de glicano de una glicoproteina
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EP4324473A3 (en) Multiparametric nucleic acid optimization
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2021006239A (es) Receptores quimericos de antigeno que tienen como diana a cd-19.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
AR095232A1 (es) Métodos y composiciones para el control de malezas
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
MX376105B (es) Método para producir l-aminoacidos utilizando una bacteria alcalifílica.
MX383142B (es) Composiciones que comprenden polipéptidos que tienen actividad xilanasa y polipéptidos que tienen actividad arabinofuranosidasa.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
EP3187214A4 (en) Electrically powered needleless injector
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
SI3169307T1 (sl) Vodni pripravek, ki vsebuje paracetamol in ibuprofen
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2016001439A (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto.
PE20230495A1 (es) Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal